LataMed AI Corp 8-K, filed Apr 13, 2026
LataMed AI Corp. (LMED)
About this 8-K
LataMed AI Corp filed this 8-K on April 13, 2026, reporting on events of February 17, 2026.
Items reported
- Item 1.01: Entered into a material agreement
- Item 2.01: Completed an acquisition or sale of assets
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 13, 2026 (
(Exact name of registrant as specified in its charter) |
|
| |||
(State or other jurisdiction of Incorporation) |
| (Commission File Number) |
| (IRS Employer Identification No.) |
(Address of principal executive offices, including zip code.)
+1
(Telephone number, including area code)
____________________________________________
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act: None.
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
N/A | N/A | N/A |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Catalyst Crew Technologies Corp.
Form 8-K
Current Report
Item 1.01 Entry into a Material Definitive Agreement
On February 17, 2026, Catalyst Crew Technologies Corp. (the “Company”) entered into an Asset Purchase Agreement (the “APA”) with its Chief Executive Officer, Kevin Rodan Levy (the “Seller”), pursuant to which the Company acquired certain assets, including intellectual property relating to an artificial intelligence-enabled healthcare analytics platform. The closing of the transactions contemplated by the APA occurred on or about February 20, 2026. The acquired assets include, among other things, proprietary software, machine learning models, datasets, and intellectual property, including certain patent registrations in Venezuela associated with the Company’s CardioAI, PulmoAI, and NeuroAI technologies.
On March 23, 2026, the Company entered into a Share Assignment Agreement with Seller pursuant to which the Company acquired one hundred percent (100%) of the issued and outstanding shares of Inversiones Long 33, C.A., a corporation organized under the laws of the Bolivarian Republic of Venezuela (the “Subsidiary”).
On April 7, 2026, the Seller entered into an Intellectual Property Assignment Agreement with the Subsidiary, pursuant to which certain intellectual property rights previously acquired by the Company pursuant to the APA were formally assigned to the Subsidiary, including:
| · | CardioAI – Registration No. VEN-SAPI-2025-005287 |
| · | PulmoAI – Registration No. VEN-SAPI-2025-009419 |
| · | NeuroAI – Registration No. VEN-SAPI-2024-033782 |
The assignment of intellectual property to the Subsidiary was an internal reorganization step intended to align the Company’s operating structure in Venezuela. The Company previously acquired such intellectual property pursuant to the APA, and the assignment to the Subsidiary did not represent a new acquisition of intellectual property. No additional consideration was paid in connection with the assignment.
The foregoing descriptions of the Asset Purchase Agreement, Share Assignment Agreement, and Intellectual Property Assignment Agreement are qualified in their entirety by reference to the full text of such agreements, copies of which are filed or will be filed as exhibits.
Item 2.01 – Completion of Acquisition or Disposition of Assets
On March 23, 2026, the Company completed the acquisition of one hundred percent (100%) of the issued and outstanding shares of Inversiones Long 33, C.A. pursuant to a Share Assignment Agreement with Kevin Rodan Levy. As a result of the foregoing, Inversiones Long 33, C.A. is a wholly-owned subsidiary of the Company. The Subsidiary was previously formed and is intended to serve as the Company’s operating entity in Venezuela and as part of its broader Latin American strategy.
Item 7.01 – Regulation FD Disclosure
On March 23, 2026, March 26, 2026, April 7, 2026, April 9, 2026, and April 13, 2026, the Company issued press releases announcing (i) the establishment of its operating structure, (ii) the assignment of intellectual property, and (iii) the introduction of its CardioAI, PulmoAI, and NeuroAI platforms, which form part of the Company’s artificial intelligence-enabled healthcare technology portfolio.
Copies of such press releases are available on publicly accessible platforms, including Yahoo Finance.
The information contained in this Item 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. Such information shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such filing.
Item 9.01 – Financial Statements and Exhibits
(d) Exhibits
Exhibit No. |
| Description |
| ||
| ||
| ||
104 |
| Cover Page Interactive Data File (embedded within the Inline XBRL document). |
*Previously filed as part of the Company’s Current Report on Form 8-K as filed with the SEC in February 25, 2026.
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: April 13, 2026
| CATALYST CREW TECHNOLOGIES CORP. | |||
| By: | /s/ Kevin Rodan Levy | ||
|
| Kevin Rodan Levy | |
| Chief Executive Officer and Director | |||
| 3 |
EXHIBIT 10.2
SHARE ASSIGNMENT AGREEMENT
This Share Assignment Agreement (the “Agreement”) is entered into as of March 23, 2026 (the “Effective Date”) by and between Kevin Rodan Levy (“Assignor”), and Catalyst Crew Technologies Corp., a Nevada corporation (the “Assignee”).
1. Assignment of Shares: Assignor hereby sells, assigns, transfers, and conveys to Assignee one hundred percent (100%) of the issued and outstanding shares of Inversiones Long 33, C.A., a corporation organized under the laws of the Bolivarian Republic of Venezuela (the “Company”), free and clear of any liens, claims, or encumbrances.
2. Consideration: This assignment is made for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged.
3. Representations and Warranties of Assignor: Assignor hereby represents and warrants to Assignee that:
|
| (a) | Assignor is the sole legal and beneficial owner of all issued and outstanding shares of the Company; |
|
| (b) | The shares are free and clear of any liens, claims, encumbrances, or restrictions of any kind; |
|
| (c) | Assignor has full power and authority to enter into this Agreement and to transfer the shares to Assignee; |
|
| (d) | No consent, approval, or authorization of any third party is required in connection with this assignment. |
4. Further Assurances: Assignor agrees to execute and deliver any additional documents and to take such further actions as may be reasonably necessary to effectuate the purposes of this Agreement, including recognizing Assignee as the sole shareholder of the Company in all applicable corporate and governmental records.
5. Entire Agreement: This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements or understandings, whether written or oral.
6. Governing Law: This Agreement shall be governed by and construed in accordance with the laws of the State of Nevada, without regard to its conflict of laws principles.
7. Counterparts: This Agreement may be executed in counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument.
IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.
ASSIGNOR:
/s/ Kevin Rodan Levy
Kevin Rodan Levy
ASSIGNEE:
Catalyst Crew Technologies Corp.
By: /s/ Kevin Rodan Levy
Name: Kevin Rodan Levy
Title: Chief Executive Officer
EXHIBIT 10.3
INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT
This Intellectual Property Assignment Agreement (this “Agreement”) is made and entered into as of April 7, 2026, by and between Kevin Rodan Levy, an individual (the “Assignor”), and Inversiones Long 33, C.A., a corporation organized under the laws of the Bolivarian Republic of Venezuela (the “Assignee”).
WITNESSETH:
WHEREAS, Assignor is the sole and exclusive owner of certain intellectual property rights relating to artificial intelligence-based healthcare analytics and diagnostic support technologies; and
WHEREAS, Assignor desires to assign such intellectual property to Assignee, and Assignee desires to acquire the same.
NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:
1. Assignment: Assignor hereby irrevocably sells, assigns, transfers, conveys, and delivers to Assignee all of Assignor’s right, title, and interest in and to the following (collectively, the “Assigned Intellectual Property”):
|
| · | CardioAI – Registration No. VEN-SAPI-2025-005287 |
|
| · | PulmoAI – Registration No. VEN-SAPI-2025-009419 |
|
| · | NeuroAI – Registration No. VEN-SAPI-2024-033782 |
together with:
|
| (a) | all inventions, discoveries, improvements, algorithms, models, processes, techniques, designs, and developments; |
|
| (b) | all trade secrets, know-how, data, databases, and proprietary information; |
|
| (c) | all rights under applicable law, international treaties, and conventions throughout the world; |
|
| (d) | all rights to use, reproduce, modify, license, sublicense, and otherwise exploit the foregoing; |
|
| (e) | all goodwill associated therewith; and |
|
| (f) | all rights to sue for past, present, and future infringement and to recover damages and other remedies. |
2. Further Assurances: Assignor agrees to execute and deliver such additional documents and take such further actions as Assignee may reasonably request to effectuate and evidence the assignment contemplated hereby.
3. Representations and Warranties: Assignor represents and warrants that:
|
| (a) | Assignor is the sole and exclusive owner of the Assigned Intellectual Property; |
|
| (b) | The Assigned Intellectual Property is free and clear of all liens, claims, and encumbrances; |
|
| (c) | No prior assignment, license, or transfer exists; and |
|
| (d) | Assignor has full power and authority to enter into this Agreement. |
4. Catch-All / Trust Provision: To the extent that any right, title, or interest in or to the Assigned Intellectual Property has not been effectively transferred to Assignee, Assignor hereby agrees to hold such rights in trust for the benefit of Assignee and shall take all actions necessary to transfer such rights to Assignee upon request.
5. Recordation: Assignor authorizes Assignee to record this Agreement with any applicable governmental authority and to take any actions necessary to evidence Assignee’s ownership of the Assigned Intellectual Property.
| 1 |
6. Power of Attorney: Assignor hereby irrevocably appoints Assignee and its officers as Assignor’s attorney-in-fact to execute and file any documents necessary to perfect, record, or enforce the rights assigned herein.
7. Entire Agreement: This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof.
8. Governing Law: This Agreement shall be governed by the laws of the State of Nevada.
9. Counterparts: This Agreement may be executed in counterparts.
IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.
ASSIGNOR:
/s/ Kevin Rodan Levy
Kevin Rodan Levy
ASSIGNEE:
Inversiones Long 33, C.A.
By: /s/ Kevin Rodan Levy
Name: Kevin Rodan Levy
Title: Authorized Representative
| 2 |